Harmony Bio earnings up next: Can margins rebound after Q4 miss?

Harmony Biosciences is expected to report Q1 EPS of $0.76 on revenue of $228.4 million, implying 34% sequential EPS improvement and 24% year-over-year revenue growth, though estimates have slipped over the past week. The key focus is margin recovery after a weak fourth quarter, alongside patent litigation over WAKIX that could extend exclusivity into 2042; analysts remain bullish with a $43 mean target versus a $32.34 share price. The stock also has support from pediatric FDA approval for pitolisant and a pipeline/NDA update expected this quarter, but near-term execution and litigation risk remain material.

Analysis

HRMY is set up as a classic “good business, bad tape” situation where the near-term debate is less about demand and more about how much of the earnings power is being deferred into later quarters. The market appears to be discounting a margin reset as structural, but the bigger second-order issue is that a successful defense of WAKIX IP would likely re-rate the stock faster than any single quarter’s EPS beat, because exclusivity duration drives the terminal multiple more than the current run-rate.

The litigation setup is asymmetric: each additional settlement or injunction materially extends the visible cash-flow runway, while a negative surprise mainly compresses the multiple rather than destroying the franchise. That creates a skew where downside from a modest miss is probably limited if management can show gross-to-net normalization, but upside from legal clarity could be substantial over the next 3-6 months as buy-side models push out generic erosion assumptions.

Consensus may be underweighting how quickly pediatric labeling and next-gen formulation initiatives can compound the base franchise if execution improves. The current valuation implies the market is paying little for the pipeline, so any evidence that the company can self-fund growth without sacrificing margins should force a revision higher in forward earnings power. The key contrarian point is that the stock may not need a flawless quarter; it mainly needs proof that the Q4 miss was seasonal, not secular.

The main risk is not the headline EPS print but a guidance cut that signals gross-to-net pressure or slower WAKIX growth into the second half. That would widen the gap between sell-side models and actual 2026 revenue potential, and given the low multiple, the stock could react more to forward commentary than to current-quarter results. Watch for litigation commentary and any change in the cadence of new patient starts, because those will determine whether this is a one-quarter digestion or the start of a longer de-rating.

Key Decisions for Investors

• Go long HRMY into the print with a 4-8 week horizon, sized as a tactical event trade; the upside case is a guidance reaffirmation plus litigation confidence, which could drive a 15-25% rerating, while downside is capped unless management flags structural margin deterioration.
• Prefer a call spread over outright equity: buy HRMY 2-4 month calls or a call spread to express upside from IP clarity, since legal wins can reprice the stock quickly but a modest earnings miss should not justify unlimited premium risk.
• If already long, hedge event risk with a short-dated put spread into earnings; the cleaner catalyst is not the quarter itself but guidance, and this reduces exposure to a negative gross-to-net surprise without fully exiting the name.
• Pair trade: long HRMY vs. short a higher-multiple, slower-growth specialty pharma peer over the next 1-2 quarters; the relative-value case is that HRMY’s low multiple underprices self-funding growth and IP optionality if execution stabilizes.
• Take profits on any pre-earnings squeeze above consensus-implied fair value if management does not materially improve full-year margin bridge; the trade works best when the market is still skeptical, not after sentiment has already reset.